| Metric | Value ($ M) | Q2 FY25 | Q3 FY24 |
|---|---|---|---|
| Revenue | 67.46 | 12.5% | 15.2% |
| Total Income | 67.46 | 12.5% | 15.2% |
| Expenditure | 162.36 | 6.5% | 10.0% |
| PBT | -93.66 | 14.6% | 10.1% |
| Net Profit | -91.25 | 18.3% | 9.2% |
| OPM | — | ||
| NPM | — | ||
| EPS | -0.25 | 24.2% | 10.7% |
Iovance Reports Q3 2025 Revenue ~$68 Million, Up 13% QoQ
04 May 2026 · 4 May, 7:44 am
Summary
Iovance Biotherapeutics reported a 13% increase in quarterly revenue, reaching approximately $68 million. The company's gross margin improved to 43% due to enhanced execution and operational efficiency. Amtagvi demand is increasing as Iovance integrates community treatment centers to drive earlier treatment and better patient outcomes. The company reaffirmed its full-year 2025 revenue guidance within the range of $250 to $300 million.
Key Highlights
- 1
Iovance Biotherapeutics reported a 13% quarterly revenue growth to approximately $68 million.
- 2
Gross margin increased to 43% due to improved execution and operational efficiency.
- 3
Amtagvi U.S. revenue contributed approximately $58 million to the total product revenue.
- 4
Cash and cash equivalents totaled approximately $307 million as of September 30, 2025, expected to fund operations into the second quarter of 2027.
- 5
Full-year 2025 revenue guidance is reaffirmed within the range of $250 to $300 million.
- 6
Health Canada granted the first Amtagvi approval outside the U.S. for patients with previously treated advanced melanoma in August 2025.
- 7
The objective response rate (ORR) was 26% and the median duration of response (mDOR) was not reached at more than 25 months of follow up for lifileucel in previously treated advanced nonsquamous NSCLC patients.
Management Comments
Frederick Vogt
We continued to see revenue growth with significant gross margin improvement in the third quarter of 2025. Amtagvi demand is increasing as we integrate our community treatment centers to drive earlier treatment and better outcomes for patients. We are building a successful commercial business, while advancing our high value development programs to address significant unmet medical needs in patients with solid tumor cancers.
Informational and educational content only. Not investment advice.